Addressing liver fibrosis by TRAIL targetied to hepatic stellate cells

Arabpour, M., 2016, [Groningen]: University of Groningen. 162 p.

Research output: ThesisThesis fully internal (DIV)Academic

Copy link to clipboard


  • Title and contents

    Final publisher's version, 167 KB, PDF document

  • Chapter 1

    Final publisher's version, 290 KB, PDF document

  • Chapter 2

    Final publisher's version, 547 KB, PDF document

  • Chapter 3

    Final publisher's version, 557 KB, PDF document

  • Chapter 4

    Final publisher's version, 1 MB, PDF document

  • Chapter 5

    Final publisher's version, 999 KB, PDF document

  • Chapter 6

    Final publisher's version, 192 KB, PDF document

  • Appendices

    Final publisher's version, 181 KB, PDF document

  • Complete thesis

    Final publisher's version, 3 MB, PDF document

  • Propositions

    Final publisher's version, 127 KB, PDF document

  • Mohammad Arabpour
Liver fibrosis is considered as an end stage liver diseases and the primary cause of need for a liver transplant. The development of liver fibrosis is associated with progressive chronic liver disease. The best anti-fibrotic therapy is the elimination of the underlying disease process. In situations in which treating the underlying etiology is not possible, a specific anti-fibrotic therapy would be highly desirable. To date, many specific anti-fibrotic treatments have been tried, but the lack of overall efficiency and the cytotoxicity associated with these treatments form a barrier for their use in the clinic. The elaboration of the underlying pathophysiology of liver fibrosis showed that, despite the complex nexus of liver injury and the fibrotic process, activated Hepatic Stellate Cells (HSC) play a central role both as a causative and as a effector cell. Therefore, research focusing on the targeted elimination of activated HSCs as the first step in natural resolution of liver fibrosis is warranted. In this research we address this issue by TRAIL targeting to HSCs. Earlier studies have shown that the increase in TRAIL receptors on the surface of HSCs during activation is associated with an increase in HSC susceptibility to the TRAIL apoptosis effect. However, the short half-life of TRAIL in vivo and the development of anti-apoptotic signaling mechanisms that cause TRAIL resistance in activated HSCs have proven to be a major hurdle in enabling the therapeutic application of TRAIL as an option in treating liver fibrosis. This thesis deals with the application of targeting TRAIL genes and proteins as a novel technology having the potential to successfully treat liver fibrosis.
Original languageEnglish
QualificationDoctor of Philosophy
Awarding Institution
Award date13-May-2016
Place of Publication[Groningen]
Print ISBNs978-90-367-8767-3
Electronic ISBNs978-90-367-8766-6
Publication statusPublished - 2016

Download statistics

No data available

ID: 31908288